Skip to main content
TEVA
NYSE Life Sciences

Teva Reports Strong Q1 Earnings, Acquires Emalex Biosciences for $700M, and Plans Share Repurchase

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$35.54
Mkt Cap
$36.811B
52W Low
$14.99
52W High
$37.345
52W Position info
137% above low
Off High info
4.8% below high
Rel. Volume info
2.9× avg
Market data snapshot near publication time

TEVA has more than doubled off its 52-week low of $14.99 on elevated volume (2.9× avg).

Summary

Teva reported significantly improved Q1 financial results, announced a major acquisition to boost its neuroscience pipeline, secured substantial R&D funding, won a key patent litigation, and plans a share repurchase program.


Key Events · Earnings and Guidance · TEVA

  • Strong Q1 Financial Performance

    Net income attributable to Teva increased by 72% to $369 million, and diluted EPS rose by 72% to $0.31. Free cash flow improved significantly by 76% to $188 million.

  • Emalex Biosciences Acquisition

    Teva entered a definitive agreement to acquire Emalex Biosciences for $700 million upfront, plus up to $200 million in milestone payments and royalties, adding a Phase 3 asset for Tourette syndrome to its neuroscience pipeline.

  • Significant R&D Funding Secured

    The company secured up to $400 million from Blackstone Life Sciences for duvakitug development and up to $500 million from Royalty Pharma for its anti-IL-15 antibody (TEV-'408) program.

  • Patent Litigation Win Against Eli Lilly

    The U.S. Appeals Court reinstated a jury verdict of infringement and a $176.5 million damages award in Teva's favor against Eli Lilly & Co. for migraine treatment patents.


Analysis · TEVA · Life Sciences

Teva Pharmaceutical Industries reported a robust first quarter, demonstrating strong execution of its 'Pivot to Growth' strategy. The company achieved significant increases in net income and diluted EPS, alongside a substantial improvement in free cash flow. A major strategic move includes the definitive agreement to acquire Emalex Biosciences for $700 million upfront, bolstering its neuroscience pipeline with a late-stage asset. Furthermore, Teva secured significant R&D funding agreements with Blackstone Life Sciences and Royalty Pharma, validating its innovative pipeline. A favorable outcome in patent litigation against Eli Lilly, reinstating a $176.5 million damages award, provides a direct financial boost. The board's instruction to plan for a share repurchase program signals confidence in future performance and commitment to shareholder returns. These combined factors indicate a strong operational and strategic quarter for Teva.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TEVA was trading at $35.54 on NYSE in the Life Sciences sector, with a market capitalization of approximately $36.8B. The 52-week trading range was $14.99 to $37.35. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TEVA - Latest Insights

TEVA
Nov 18, 2026, 5:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $42.21
Real-time Price: $42.00 info
Change: -$0.2089 (-0.49%) info
Market Cap: $49.275B info
TEVA
Nov 16, 2026, 12:36 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $43.62
Real-time Price: $42.00 info
Change: -$1.62 (-4%) info
Market Cap: $49.275B info
TEVA
Nov 11, 2026, 12:33 PM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $42.86
Real-time Price: $42.00 info
Change: -$0.860 (-2%) info
Market Cap: $49.275B info
TEVA
Nov 03, 2026, 7:58 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $41.60
Real-time Price: $42.00 info
Change: +$0.400 (+0.96%) info
Market Cap: $49.275B info
TEVA
Oct 09, 2026, 11:21 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $41.62
Real-time Price: $42.00 info
Change: +$0.385 (+0.93%) info
Market Cap: $49.275B info